IL6 and COVID-19: Therapeutic modulation of IL-6 levels by anti-IL-6 receptor monoclonal antibodies (mAbs) (tocilizumab, sarilumab) and anti-IL6 mAbs reduces the duration and/or severity of COVID-19 (87–90).